Cara Therapeutics Reports Third Quarter 2022 Financial Results
November 07, 2022 16:01 ET
|
Cara Therapeutics, Inc.
– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection – – Strong demand for KORSUVA injection driven by large dialysis organizations with...
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
November 03, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
October 24, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
September 28, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
September 12, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
September 08, 2022 08:15 ET
|
Cara Therapeutics, Inc.
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Significant reduction of itch intensity was evident at Day 1 and effect was...
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
August 24, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
August 22, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...